[1]
|
Schultz, S.K. and Andreasen, N.C. (1999) Schizophrenia. Lancet, 353, 1425-1430.
doi:10.1016/S0140-6736(98)07549-7
|
[2]
|
Seeman, P. (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse, 1, 133-52.
doi:10.1002/syn.890010203
|
[3]
|
Howes, O.D. and Kapur, S. (2009) The dopamine hypothesis of schizophrenia: Version III-the final common pathway. Schizophr Bull, 35, 549-562.
doi:10.1093/schbul/sbp006
|
[4]
|
Kerwin, R. (2000) From pharmacological profiles to clinical outcomes. International Clinical Psychopharmacology, 15, S1-S4.
|
[5]
|
Missale, C., Nash, S.R., Robinson, S.W., et al. (1998) Dopamine receptors: From structure to function. Physiological Review, 78, 189-225.
|
[6]
|
Sibley, D.R., Monsma, F.J.Jr. and Shen, Y. (1993) Molecular neurobiology of dopaminergic receptors. International Review of Neurobiology, 35, 391-415.
doi:10.1016/S0074-7742(08)60573-5
|
[7]
|
Landwehrmeyer, B., Mengod, G. and Palacios, J.M. (1993) Dopamine D3 receptor mRNA and binding sites in human brain. Molecular Brain Research, 18, 187-92.
doi:10.1016/0169-328X(93)90188-U
|
[8]
|
Meador-Woodruff, J.H., Damask, S.P., Wang, J., et al. (1996) Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology, 15, 17-29. doi:10.1016/0893-133X(95)00150-C
|
[9]
|
Suzuki, M., Hurd, Y.L., Sokoloff, P., et al. (1998) D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Research, 779, 58-74.
doi:10.1016/S0006-8993(97)01078-0
|
[10]
|
Meador-Woodruff, J.H., Grandy, D.K., Van Tol, H.H., et al. (1994) Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacology, 10, 239-248.
|
[11]
|
Meador-Woodruff, J.H., Haroutunian, V., Powchik, P., et al. (1997) Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Archives of General Psychiatry, 54, 1089-1095.
|
[12]
|
Matsumoto, M., Hidaka, K., Tada, S., et al. (1996) Low levels of mRNA for dopamine D4 receptor in human cerebral cortex and striatum. Journal of Neurochemistry, 66, 915-919. doi:10.1046/j.1471-4159.1996.66030915.x
|
[13]
|
Mulcrone, J. and Kerwin, R.W. (1996) No difference in the expression of the D4 gene in post-mortem frontal cortex from controls and schizophrenics. Neuroscience Letters, 219, 163-166.
doi:10.1016/S0304-3940(96)13191-8
|
[14]
|
Schmauss, C., Haroutunian, V., Davis, K.L., et al. (1993) Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proceeding of National Academy Science of United States of America, 90, 8942-8946.
doi:10.1073/pnas.90.19.8942
|
[15]
|
Reynolds, G.P., Yao, Z., Zhang, X., et al. (2005) Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. European Neuropsychopharmacology, 15, 143-151.
doi:10.1016/j.euroneuro.2004.07.001
|
[16]
|
Herrmann, M.J., Walter, A., Schreppel, T., et al. (2007) D4 receptor gene variation modulates activation of prefrontal cortex during working memory. Neuroscience, 26, 2713-2718. doi:10.1111/j.1460-9568.2007.05921.x
|
[17]
|
Zhang, K., Grady, C.J., Tsapakis, E.M., et al. (2004) Regulation of working memory by dopamine D4 receptor in rats. Neuropsychopharmacology, 29, 1648-1655.
doi:10.1038/sj.npp.1300491
|
[18]
|
Qiu, Y., Peng, Y. and Wang, J. (1996) Immunoregulatory role of neurotransmitters. Advance in Neuroimmunology, 6, 223-231. doi:10.1016/S0960-5428(96)00018-6
|
[19]
|
Josefsson, E., Bergquist, J., Ekman, R., et al. (1996) Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis. Immunology, 88, 140-146.
doi:10.1046/j.1365-2567.1996.d01-653.x
|
[20]
|
Kirillova, G.P., Hrutkay, R.J., Shurin, M.R., et al. (2008) Dopamine receptors in human lymphocytes: Radioligand binding and quantitative RT-PCR assays. Journal of Neuroscience Methods, 174, 272-280.
doi:10.1016/j.jneumeth.2008.07.018
|
[21]
|
Sarkar, C., Das, S., Chakroborty, D., et al. (2006) Cutting Edge: Stimulation of dopamine D4 receptors induce T cell quiescence by up-regulating Kruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation. Journal of Immunology, 177, 7525-7529.
|
[22]
|
Vile, J.M. and Strange, P.G. (1996) D2-like dopamine receptors are not detectable on human peripheral blood lymphocytes. Official Journal of the Society of Biological Psychiatry, 40, 881-885.
doi:10.1016/0006-3223(95)00498-X
|
[23]
|
Amenta, F., Bronzetti, E., Felici, L., et al. (1999) Dopamine D2-like receptors on human peripheral blood lymphocytes: A radioligand binding assay and immunocytochemical study. Autonomic and Autacoid Pharmacology, 19, 151-159. doi:10.1046/j.1365-2680.1999.00135.x
|
[24]
|
Ricci, A., Bronzetti, E., Felici, L., et al. (1998) Labeling of dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes with [3H]7-OH-DPAT: A combined radioligand binding assay and immunochemical study. Journal of Neuroimmunology, 92, 191-195.
doi:10.1016/S0165-5728(98)00207-0
|
[25]
|
Ilani, T., Ben-Shachar, D., Strous, R.D., et al. (2001) A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proceeding of National Academy Science of the United States of America, 98, 625-628.
doi:10.1073/pnas.021535398
|
[26]
|
Kwak, Y.T., Koo, M.S., Choi, C.H., et al. (2001) Change of dopamine receptor mRNA expression in lymphocyte of schizophrenic patients. BMC Medical Genetics, 2, 3. doi:10.1186/1471-2350-2-3
|
[27]
|
Boneberg, E.M., von Seydlitz, E., Propster, K., et al. (2006) D3 dopamine receptor mRNA is elevated in T cells of schizophrenic patients whereas D4 dopamine receptor mRNA is reduced in CD4+ -T cells. Journal of Neuroimmunology, 173, 180-187.
doi:10.1016/j.jneuroim.2005.11.018
|
[28]
|
Czermak, C., Lehofer, M., Renger, H., et al. (2004) Dopamine receptor D3 mRNA expression in human lymphocytes is negatively correlated with the personality trait of persistence. Journal of Neuroimmunology, 150, 145-149. doi:10.1016/j.jneuroim.2004.01.009
|
[29]
|
Rodrigues, K.P., Souza, P.A., Lima, P.M., et al. (2005) Expression of D3 and D4 dopamine receptors in leukocytes is related to schizophrenic symptoms. Schizophrenia Research, 80, 363-365.
doi:10.1016/j.schres.2005.06.010
|
[30]
|
Constantinidis, C., Williams, G.V. and Goldman-Rakic, P.S. (2002) A role for inhibition in shaping the temporal flow of information in prefrontal cortex. Nature Neuroscience, 5, 175-180. doi:10.1038/nn799
|
[31]
|
Lewis, D.A., Hashimoto, T. and Volk, D.W. (2005) Cortical inhibitory neurons and schizophrenia. Nature Review Neuroscience, 6, 312-324. doi:10.1038/nrn1648
|
[32]
|
Yuen, E.Y. and Yan, Z. (2009) Dopamine D4 receptors regulate AMPA receptor trafficking and glutamatergic transmission in GABAergic interneurons of prefrontal cortex. Journal of Neuroscience, 29, 550-562.
doi:10.1523/JNEUROSCI.5050-08.2009
|
[33]
|
Graziane, N.M., Yuen, E.Y. and Yan, Z. (2009) Dopamine D4 receptors regulate GABAA receptor trafficking via an actin/cofilin/myosin-dependent mechanism. Journal of Biological Chemistry, 284, 8329-8336.
doi:10.1074/jbc.M807387200
|
[34]
|
Engelhardt, B. (2008) Immune cell entry into the central nervous system: Involvement of adhesion molecules and chemokines. Journal of Neurological Science, 274, 23-26. doi:10.1016/j.jns.2008.05.019
|
[35]
|
Brochard, V., Combadiere, B., Prigent, A., et al. (2009) Infiltration of CD4 + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. Journal of Clinical Investigation, 119, 182-192.
doi:10.1172/JCI36470
|
[36]
|
Sullivan, P.F., Fan, C. and Perou, C.M. (2006) Evaluating the comparability of gene expression in blood and brain. American Journal of Medical Genetics, 141B, 261-268.
doi:10.1002/ajmg.b.30272
|
[37]
|
Padin, J.F., Rodriguez, M.A., Dominguez, E., et al. (2006) Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells. Neuropharmacology, 51, 923-932. doi:10.1016/j.neuropharm.2006.06.005
|